Health Care & Life Sciences » Biotechnology | United Therapeutics Corp.

United Therapeutics Corp. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,117
1,289
1,466
1,599
1,725
1,628
Cost of Goods Sold (COGS) incl. D&A
131
126
69
73
106
199
Gross Income
986
1,163
1,397
1,526
1,620
1,429
SG&A Expense
693
624
698
464
595
618
EBIT
292
539
699
1,062
1,025
811
Unusual Expense
-
1
-
-
260
59
Non Operating Income/Expense
-
5
350
2
13
8
Interest Expense
18
18
5
4
9
14
Pretax Income
279
525
1,044
1,060
770
759
Income Tax
104
185
393
347
352
170
Consolidated Net Income
175
340
652
714
418
589
Net Income
175
340
652
714
418
589
Net Income After Extraordinaries
175
340
652
714
418
589
Net Income Available to Common
175
340
652
714
418
589
EPS (Basic)
3.28
6.28
12.72
15.25
9.31
13.39
Basic Shares Outstanding
50
48
46
44
44
44
EPS (Diluted)
3.28
6.28
12.72
15.25
9.31
13.39
Diluted Shares Outstanding
53
54
51
47
45
44
EBITDA
324
571
732
1,093
1,056
847
Non-Operating Interest Income
4
-
-
-
-
29

About United Therapeutics

View Profile
Address
1040 Spring Street
Silver Spring Maryland 20910
United States
Employees -
Website http://www.unither.com
Updated 07/08/2019
United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.